Pentixapharm Holding AG (XTER:PTP) EV-to-FCF: -3.24 (As of Jun. 29, 2026)


XTER:PTP Pentixapharm Holding AG XTER:PTP
20 GF Score
Price €2.22
! 2 Warning Signs
View Full Analysis

What is Pentixapharm Holding AG EV-to-FCF?

Pentixapharm Holding AG XTER:PTP -6.33% 20 EV-to-FCF is -3.24 as of Jun. 29, 2026. GuruFocus rates XTER:PTP with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 336 Biotechnology companies, Pentixapharm Holding AG ranks worse than 297618.75% on this metric.

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pentixapharm Holding AG's Enterprise Value is €49.36 Mil. Pentixapharm Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-15.22 Mil. Therefore, Pentixapharm Holding AG's EV-to-FCF for today is -3.24.

The historical rank and industry rank for Pentixapharm Holding AG's EV-to-FCF or its related term are showing as below:

XTER:PTP' s EV-to-FCF Range Over the Past 10 Years
Min: -9.67   Med: -3.02   Max: -1.61
Current: -3.24

During the past 5 years, the highest EV-to-FCF of Pentixapharm Holding AG was -1.61. The lowest was -9.67. And the median was -3.02.

XTER:PTP's EV-to-FCF is ranked worse than
100% of 336 companies
in the Biotechnology industry
Industry Median: 14.885 vs XTER:PTP: -3.24

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-06-29), Pentixapharm Holding AG's stock price is €2.22. Pentixapharm Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.640. Therefore, Pentixapharm Holding AG's PE Ratio (TTM) for today is At Loss.


Pentixapharm Holding AG  (XTER:PTP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Pentixapharm Holding AG's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.22/-0.640
=At Loss

Pentixapharm Holding AG's share price for today is €2.22.
Pentixapharm Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.640.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pentixapharm Holding AG EV-to-FCF Related Terms


Pentixapharm Holding AG EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG EV-to-FCF Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-FCF
0.00 0.00 0.00 -11.13 -1.64

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -9.73 -4.17 -2.18 -1.64 -2.62

XTER:PTP vs VRTX, REGN, ALNY: EV-to-FCF Comparison

For the Biotechnology subindustry, Pentixapharm Holding AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pentixapharm Holding AG EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pentixapharm Holding AG's EV-to-FCF falls into.


XTER:PTP
20GF Score
Pentixapharm Holding AG XTER:PTP
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG EV-to-FCF Calculation

Pentixapharm Holding AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=49.360/-15.223
=-3.24

Pentixapharm Holding AG's current Enterprise Value is €49.36 Mil.
Pentixapharm Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-15.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-FCF →
What does a EV-to-FCF of -3.24 mean?
Pentixapharm Holding AG (XTER:PTP) has a EV-to-FCF of -3.24 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pentixapharm Holding AG and its competitors. According to the industry distribution chart, Pentixapharm Holding AG ranks #999999 out of 336 companies in the Biotechnology industry.
Is Pentixapharm Holding AG's EV-to-FCF too high?
Pentixapharm Holding AG's current EV-to-FCF is -3.24. Based on the distribution chart, Pentixapharm Holding AG ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pentixapharm Holding AG ranks #999999 out of 336 companies for EV-to-FCF. This places Pentixapharm Holding AG in the lower half of its industry. The industry median EV-to-FCF is 14.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.89, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pentixapharm Holding AG and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pentixapharm Holding AG's current EV-to-FCF is -3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (XTER:PTP) has a current EV-to-FCF of -3.24. The current EV-to-FCF is -3.24. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pentixapharm Holding AG (XTER:PTP), the current EV-to-FCF is -3.24 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score

Get the complete analysis for XTER:PTP

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.22
Price